BioSpace News Archive

Rising prevalence of different types of cancer and increasing government investments in R&D activities in the field of cancer immunotherapy are some of the major factors driving Cancer Immunotherapy market revenue growth.

Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics today announced a strategic collaboration to advance novel targeted protein degrader therapies to address important areas of medical need.

AbbVie (NYSE: ABBV), today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for IMBRUVICA®.

Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study for the refinement and further development of its multiomics platform to detect multiple cancers.

In honor of Rare Disease Day on February 28 and the 25-30 million Americans living with rare diseases,1 the Janssen Pharmaceutical Companies of Johnson & Johnson announced the launch of the refreshed iMaGineMyMG, a national campaign aimed to increase awareness of myasthenia gravis, a chronic autoimmune neuromuscular disorder, and provide support to people living with the condition.

Amyris, Inc. today announced that management will participate in a fireside chat at the 42 nd Annual Cowen Health Care Conference on Monday, March 7, 2022.

Element Biosciences Inc. today announced partnerships with both Google DeepVariant and Sentieon for variant calling analysis.

Twist Bioscience Corporation today announced it has become a part of the Digital Preservation Coalition’s (DPC) Supporter Program, where members and solution providers can collaborate.

Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced preliminary unaudited revenue for the fourth quarter ended December 31, 2021, of $10.0 to $10.1 million, including Sample Transport of approximately $0.5 million.

Element Biosciences Inc. today announced a partnership with Fabric Genomics Inc. to explore commercialization of end-to-end clinical application solutions based on Element’s AVITI system and the Fabric Enterprise clinical interpretation platform.